Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    November 2017
  1. BARANSKI AC, Schafer M, Bauder-Wust U, Roscher M, et al
    PSMA-11 Derived Dual-labeled PSMA-Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
    J Nucl Med. 2017 Nov 30. pii: jnumed.117.201293. doi: 10.2967/jnumed.117.201293.
    PubMed     Text format     Abstract available


  2. ZHANG J, Niu G, Fan X, Lang L, et al
    Positron Emission Tomography Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198929. doi: 10.2967/jnumed.117.198929.
    PubMed     Text format     Abstract available


  3. CALAIS J, Czernin J, Cao M, Kishan AU, et al
    68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749.
    PubMed     Text format     Abstract available


  4. EIBER M, Herrmann K, Calais J, Hadaschihk B, et al
    PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.
    PubMed     Text format     Abstract available


  5. GIESEL FL, Kopka K
    Reply: PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198176. doi: 10.2967/jnumed.117.198176.
    PubMed     Text format    


    October 2017
  6. MINAMIMOTO R, Sonni I, Hancock S, Vasanawala S, et al
    Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
    J Nucl Med. 2017 Oct 30. pii: jnumed.117.197624. doi: 10.2967/jnumed.117.197624.
    PubMed     Text format     Abstract available


  7. HOFMAN MS, Eu P, Jackson P, Hong E, et al
    Cold Kit PSMA PET Imaging: Phase I study of 68Ga-THP-PSMA PET/CT in patients with prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.199554. doi: 10.2967/jnumed.117.199554.
    PubMed     Text format     Abstract available


  8. ELSCHOT M, Selnaes KM, Sandsmark E, Kruger-Stokke B, et al
    Combined 18F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.198598. doi: 10.2967/jnumed.117.198598.
    PubMed     Text format     Abstract available


  9. DONIN NM, Reiter R
    Why targeting PSMA is a game changer in the management of prostate cancer - a Urologist's point of view.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.191874. doi: 10.2967/jnumed.117.191874.
    PubMed     Text format     Abstract available


  10. KRATOCHWIL C, Bruchertseifer F, Rathke H, Bronzel M, et al
    Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
    J Nucl Med. 2017;58:1624-1631.
    PubMed     Text format     Abstract available


    September 2017
  11. IAGARU A
    Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    J Nucl Med. 2017 Sep 28. pii: jnumed.117.198192. doi: 10.2967/jnumed.117.198192.
    PubMed     Text format    


  12. FENDLER WP, Cutler C
    More alpha than beta for prostate cancer?
    J Nucl Med. 2017 Sep 21. pii: jnumed.117.198333. doi: 10.2967/jnumed.117.198333.
    PubMed     Text format    


  13. PICCARDO A, Paparo F, Puntoni M, Righi S, et al
    64CuCl2 PET/CT in prostate cancer relapse.
    J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628.
    PubMed     Text format     Abstract available


  14. FOSBOL MO, Petersen PM, Kjaer A, Mortensen J, et al
    Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.195677. doi: 10.2967/jnumed.117.195677.
    PubMed     Text format     Abstract available


  15. SANO K, Kanada Y, Kanazaki K, Ding N, et al
    Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.
    J Nucl Med. 2017;58:1380-1385.
    PubMed     Text format     Abstract available


    August 2017
  16. WOYTHAL N, Arsenic R, Kempkensteffen C, Miller K, et al
    Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer.
    J Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
    PubMed     Text format     Abstract available


    July 2017
  17. AFAQ A, Alahmed S, Chen SH, Lengana T, et al
    68Ga-PSMA PET/CT impact on prostate cancer management.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.192625. doi: 10.2967/jnumed.117.192625.
    PubMed     Text format     Abstract available


  18. GRIVAS N, Wit E, Kuusk T, KleinJan G, et al
    The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on the biochemical recurrence of prostate cancer patients treated with robot-assisted radical prostatectomy.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.195644. doi: 10.2967/jnumed.117.195644.
    PubMed     Text format     Abstract available


  19. SCHWARZENBOCK SM, Rauscher I, Bluemel C, Fendler WP, et al
    PSMA Ligands for PET-Imaging of Prostate Cancer.
    J Nucl Med. 2017 Jul 7. pii: jnumed.117.191031. doi: 10.2967/jnumed.117.191031.
    PubMed     Text format     Abstract available


    June 2017
  20. FENDLER WP, Rahbar K, Herrmann K, Kratochwil C, et al
    177Lu-PSMA radioligand therapy for prostate cancer.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.191023. doi: 10.2967/jnumed.117.191023.
    PubMed     Text format     Abstract available


  21. AL-MOMANI E, Machulla HJ
    PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.197996. doi: 10.2967/jnumed.117.197996.
    PubMed     Text format    


  22. ROACH PJ, Francis R, Emmett L, Hsiao E, et al
    The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160.
    PubMed     Text format     Abstract available


  23. HOFMAN MS
    Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT?
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.192542. doi: 10.2967/jnumed.117.192542.
    PubMed     Text format    


  24. VINSENSIA M, Choyke PL, Hadaschik B, Holland-Letz T, et al
    68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.116.185033. doi: 10.2967/jnumed.116.185033.
    PubMed     Text format     Abstract available


  25. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Detection of Synchronous Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.190215. doi: 10.2967/jnumed.117.190215.
    PubMed     Text format     Abstract available


    May 2017
  26. FENDLER WP, Stuparu AD, Evans-Axelsson S, Luckerath K, et al
    Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
    J Nucl Med. 2017 May 25. pii: jnumed.117.193359. doi: 10.2967/jnumed.117.193359.
    PubMed     Text format     Abstract available


  27. BIETH M, Kronke M, Tauber R, Dahlbender M, et al
    Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using 68Ga-PSMA-PET/CT.
    J Nucl Med. 2017 May 25. pii: jnumed.116.189050. doi: 10.2967/jnumed.116.189050.
    PubMed     Text format     Abstract available


  28. JACOBSON O, Chen H, Niu G, Kiesewetter DO, et al
    PET-guided evaluation and optimization of internalized antibody-drug conjugates targeting erythropoietin producing hepatoma A2 receptor.
    J Nucl Med. 2017 May 25. pii: jnumed.117.192245. doi: 10.2967/jnumed.117.192245.
    PubMed     Text format     Abstract available


  29. HOPE TA, Aggarwal R, Chee B, Tao D, et al
    Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192476. doi: 10.2967/jnumed.117.192476.
    PubMed     Text format     Abstract available


  30. SCHMUCK S, von Klot CA, Henkenberens C, Sohns JM, et al
    Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.193581. doi: 10.2967/jnumed.117.193581.
    PubMed     Text format     Abstract available


  31. HADASCHIK B, Boegemann M
    Why Targeting PSMA is a valuable addition in the management of castration-resistant prostate cancer: The Urologists' point of view.
    J Nucl Med. 2017 May 18. pii: jnumed.117.194753. doi: 10.2967/jnumed.117.194753.
    PubMed     Text format    


  32. KESCH C, Vinsensia M, Radtke JP, Schlemmer HP, et al
    Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study.
    J Nucl Med. 2017 May 4. pii: jnumed.116.189233. doi: 10.2967/jnumed.116.189233.
    PubMed     Text format     Abstract available


    April 2017
  33. WONDERGEM M, van der Zant F, Knol R, Lazarenko S, et al
    18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.192658. doi: 10.2967/jnumed.117.192658.
    PubMed     Text format     Abstract available


  34. KELLY JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, et al
    Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.188722. doi: 10.2967/jnumed.116.188722.
    PubMed     Text format     Abstract available


  35. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Text format     Abstract available


  36. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Text format     Abstract available


  37. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Text format     Abstract available


  38. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Text format     Abstract available


    March 2017
  39. GOFFIN KE, Joniau S, Tenke P, Slawin K, et al
    Phase 2 study of 99mTc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.187807. doi: 10.2967/jnumed.116.187807.
    PubMed     Text format     Abstract available


  40. PIERT M, Shao X, Raffel DM, Davenport MS, et al
    Preclinical evaluation of 11C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.173179. doi: 10.2967/jnumed.116.173179.
    PubMed     Text format     Abstract available


    February 2017
  41. EINSPIELER I, Rauscher I, Duwel C, Kronke M, et al
    Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.184457. doi: 10.2967/jnumed.116.184457.
    PubMed     Text format     Abstract available


    January 2017
  42. AFSHAR-OROMIEH A, Sattler LP, Mier W, Hadaschik B, et al
    The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer.
    J Nucl Med. 2017 Jan 6. pii: jnumed.116.183483. doi: 10.2967/jnumed.116.183483.
    PubMed     Text format     Abstract available


    December 2016
  43. LI X, Rowe SP, Leal JP, Gorin MA, et al
    Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739.
    PubMed     Text format     Abstract available


  44. DIETLEIN F, Kobe C, Neubauer S, Schmidt M, et al
    PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2016 Dec 1. pii: jnumed.116.185538.
    PubMed     Text format     Abstract available


    October 2016
  45. CARDINALE J, Schafer M, Benesova M, Bauder-Wust U, et al
    Preclinical Evaluation of [18F]PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.181768.
    PubMed     Text format     Abstract available


  46. RAHBAR K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, et al
    German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.183194.
    PubMed     Text format     Abstract available


  47. KULKARNI HR, Singh A, Schuchardt C, Niepsch K, et al
    PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  48. ROWE SP, Drzezga A, Neumaier B, Dietlein M, et al
    Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  49. AFSHAR-OROMIEH A, Babich JW, Kratochwil C, Giesel FL, et al
    The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  50. PANDIT-TASKAR N, Veach DR, Fox JJ, Scher HI, et al
    Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  51. BALLAS LK, de Castro Abreu AL, Quinn DI
    What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  52. MANSI R, Minamimoto R, Macke H, Iagaru AH, et al
    Bombesin-Targeted PET of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  53. SCHUSTER DM, Nanni C, Fanti S
    Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  54. BEHESHTI M, Rezaee A, Geinitz H, Loidl W, et al
    Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  55. CECI F, Castellucci P, Mapelli P, Incerti E, et al
    Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  56. MAPELLI P, Incerti E, Ceci F, Castellucci P, et al
    11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  57. WEBER WA, Morris MJ
    Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  58. NITSCH S, Hakenberg OW, Heuschkel M, Drager D, et al
    Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  59. SPICK C, Herrmann K, Czernin J
    Evaluation of Prostate Cancer with 11C-Acetate PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  60. JADVAR H
    PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  61. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  62. IAGARU AH, Mittra E, Colletti PM, Jadvar H, et al
    Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  63. CHEN FK, de Castro Abreu AL, Palmer SL
    Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  64. LINDENBERG L, Ahlman M, Turkbey B, Mena E, et al
    Evaluation of Prostate Cancer with PET/MRI.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  65. KILCOYNE A, Harisinghani MG, Mahmood U
    Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


    September 2016
  66. AHMADZADEHFAR H, Azgomi K, Hauser S, Wei X, et al
    68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178533.
    PubMed     Text format     Abstract available


  67. OKAMOTO S, Thieme A, Allmann J, D'Alessandria C, et al
    Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178483.
    PubMed     Text format     Abstract available


  68. HOPE TA, Truillet CC, Ehman EC, Afshar-Oromieh A, et al
    Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.181800.
    PubMed     Text format     Abstract available


  69. ROBU S, Schottelius M, Eiber M, Maurer T, et al
    Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer.
    J Nucl Med. 2016 Sep 15. pii: jnumed.116.178939.
    PubMed     Text format     Abstract available


  70. JANI A, Schreibmann E, Rossi PJ, Shelton JW, et al
    Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.176057.
    PubMed     Text format     Abstract available


  71. FERDINANDUS J, Eppard E, Gartner F, Kurpig S, et al
    Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178228.
    PubMed     Text format     Abstract available


    August 2016
  72. OYEN WJ, de Bono JS
    Targeted alpha-based treatment of metastatic castration-resistant prostate cancer patients: revolutionizing systemic radiotherapy?
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.179887.
    PubMed     Text format    


  73. DE BOER P, Piet AH, Oprea-Lager DE, Slotman B, et al
    Letter: PET-guided stereotactic irradiation of prostate cancer lymph node metastases.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.181149.
    PubMed     Text format    


  74. D'SOUZA JW, Hensley H, Doss M, Beigarten C, et al
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.178780.
    PubMed     Text format     Abstract available


  75. PANDIT-TASKAR N, O'Donoghue JA, Ruan S, Lyashchenko S, et al
    First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176206.
    PubMed     Text format     Abstract available


  76. ZHANG H, Desai P, Koike Y, Houghton J, et al
    Dual modality imaging of prostate cancer with a fluorescent and radiogallium-labeled GRP receptor antagonist.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176099.
    PubMed     Text format     Abstract available


  77. NOCK BA, Kaloudi A, Lymperis E, Giarika A, et al
    Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1 - Preclinical and first clinical results.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.178889.
    PubMed     Text format     Abstract available


  78. ZHANG J, Niu G, Lang L, Li F, et al
    Clinical translation of a dual integrin alphavbeta3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.177048.
    PubMed     Text format     Abstract available


    July 2016
  79. LIN C, Bradshaw TJ, Perk TG, Harmon S, et al
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    J Nucl Med. 2016 Jul 21. pii: jnumed.116.177295.
    PubMed     Text format     Abstract available


  80. HARADA N, Kimura H, Onoe S, Watanabe H, et al
    Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer.
    J Nucl Med. 2016 Jul 14. pii: jnumed.116.175810.
    PubMed     Text format     Abstract available


  81. KRATOCHWIL C, Bruchertseifer F, Giesel FL, Weis M, et al
    225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Jul 7. pii: jnumed.116.178673.
    PubMed     Text format     Abstract available


    June 2016
  82. RAUSCHER I, Maurer T, Beer AJ, Graner FP, et al
    Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.173492.
    PubMed     Text format     Abstract available


  83. FENDLER WP, Schmidt DF, Wenter V, Thierfelder KM, et al
    68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.172627.
    PubMed     Text format     Abstract available


    May 2016
  84. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Text format     Abstract available


    April 2016
  85. RAHBAR K, Schmidt M, Heinzel A, Eppard E, et al
    Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis.
    J Nucl Med. 2016 Apr 7. pii: jnumed.116.173757.
    PubMed     Text format     Abstract available


    March 2016
  86. KRATOCHWIL C, Giesel FL, Stefanova M, Benesova M, et al
    PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.171397.
    PubMed     Text format     Abstract available


  87. PIERT M, Montgomery J, Kunju LP, Siddiqui J, et al
    18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.170878.
    PubMed     Text format     Abstract available


    February 2016
  88. KWEKKEBOOM DJ
    Perspective on 177Lu-PSMA therapy of metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Feb 18. pii: jnumed.115.171363.
    PubMed     Text format    


  89. LEE JH, Sato M, Coel MN, Lee KH, et al
    Prediction of PSA Progression in Castrate-Resistant Prostate Cancer based on Treatment-Associated Change in Tumor Burden Quantified by 18F-fluorocholine PET/CT.
    J Nucl Med. 2016 Feb 16. pii: jnumed.115.169177.
    PubMed     Text format     Abstract available


    January 2016
  90. APOLO AB, Lindenberg L, Shih JH, Mena E, et al
    Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.166512.
    PubMed     Text format     Abstract available


  91. BAUM RP, Kulkarni HR, Schuchardt C, Singh A, et al
    Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.168443.
    PubMed     Text format     Abstract available


  92. RAHBAR K, Weckesser M, Huss S, Semjonow A, et al
    Correlation of intraprostatic tumor extent with 68-Ga-PSMA distribution in patients with prostate cancer.
    J Nucl Med. 2016 Jan 14. pii: jnumed.115.169243.
    PubMed     Text format     Abstract available


  93. LARSON SM
    EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan.
    J Nucl Med. 2016;57:5-6.
    PubMed     Text format    


    December 2015
  94. OPREA-LAGER DE, Kramer G, van de Ven P, van den Eertwegh A, et al
    Repeatability of quantitative 18F-fluoromethylcholine PET/CT studies in prostate cancer.
    J Nucl Med. 2015 Dec 23. pii: jnumed.115.167692.
    PubMed     Text format     Abstract available


  95. MINAMIMOTO R, Hancock S, Schneider B, Chin F, et al
    Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2015 Dec 10. pii: jnumed.115.168393.
    PubMed     Text format     Abstract available


    November 2015
  96. PYKA T, Weirich G, Einspieler I, Maurer T, et al
    [68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.164442.
    PubMed     Text format     Abstract available


  97. VERWER EE, Lammertsma AA, Boellaard R
    Reply: Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806-7.
    PubMed     Text format    


  98. LAFFON E, de Clermont H, Marthan R
    Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806.
    PubMed     Text format    


    September 2015
  99. MINAMIMOTO R, Loening A, Jamali M, Barkhodari A, et al
    Prospective Comparison of 99mTc MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT and Whole-Body MRI in Patients with Breast and Prostate Cancers.
    J Nucl Med. 2015 Sep 24. pii: jnumed.115.162610.
    PubMed     Text format     Abstract available


    July 2015
  100. KIESS A, Minn I, Chen Y, Hobbs RF, et al
    Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    J Nucl Med. 2015 Jul 16. pii: jnumed.115.155929.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: